THREAD: From AstraZeneca Q&A with @CDCgov #ACIP on its #COVID19 vaccine: Further analysis suggests greater efficacy in low-dose/high-dose group is actually due to greater interval between doses, not the dosing itself. 
“[W]e think that interval actually what is probably associated with the increased efficacy that we’re seeing for that low-dose standard-dose group just because many of those participants were in the longer interval group.” - Tonya Villafana, AstraZeneca
The perplexing claim of 90% efficiency for this dosing regime was one of several questions other experts had for Oxford University after the release of results from its trials of the vaccine.
buzzfeednews.com/article/petera…
buzzfeednews.com/article/petera…
Comment in from vaccine expert John Moore of Weill Cornell: "The only data on the Oxford/AZ vaccine that I’m interested in seeing is the outcome of the Phase 3 trial in the USA that is being conducted to the standards required by the FDA."
And from Natalie Dean, biostatistician at U Florida: "This is why we avoid relying upon post hoc explanations to unexpected scientific results. In their initial press release, Oxford AstraZeneca led with the low dose as the driver ... but there was always more to the story."
• • •
Missing some Tweet in this thread? You can try to
force a refresh
